**Characteristics of included studies according to type of oxygen support and corticosteroid use**

|  |  |  |
| --- | --- | --- |
| **Study Characteristics** | **Tocilizumab group** | **Control group** |
| **RECOVERY**  **Age – yr (SD)**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  Simple oxygen only  Noninvasive ventilation  Invasive mechanical ventilation or ECMO  **Corticosteroids, n (%)**  **REMAP - CAP**  **Age – yr**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  None or simple oxygen only  High flow nasal cannulae \*  Noninvasive ventilation  Invasive mechanical ventilation or ECMO  **Corticosteroids (%)** | **(N=2022)**  63.3 (13.7)  1337 (66)  935/2022 (46)  819/2022 (41)  268/2022 (13)  1664 (82)  **(N=353)**  61,5 ± 12,5  261(74)  1/353 (1)  101/353 (42)  147/353 (29)  104/353 (29)  ~90 \*\* | **(N=2094)**  63.9(13.6)  1437 (69)  933/2094 (45)  867/2094 (41)  294/2094 (14)  1721 (82)  **(N=402)**  61,1±12,8  283(70)  2/402 (1)  110/402 (27)  169/402 (42)  121/402 (30)  91 |
| **CORIMUNO – 19**  **Age – yr – mean IQR**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  Simple oxygen only  **Corticosteroids, n (%)** | **(N = 63)**  64,0 (57,1 – 74,3)  44/63 (70)  63/63 (100)  21/63 (33) \*\*\* | **(N = 67)**  63,3 (57,1 -72,3)  44/67(66)  67/67 (100)  41/67 (61) \*\*\* |
| **COVACTA**  **Age – yr - mean**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  No supplemental oxygen  Simple oxygen only  Noninvasive ventilation  Invasive mechanical ventilation or ECMO  **Corticosteroids, n (%)** | **(N=294)**  60.9±14,6  205 (70)  9/294 (3)  78/294 (26)  94/294 (32)  113/294 (38)  106 (36) | **(N=144)**  60.6±13.7  101 (70)  6/144 (4)  44/144 (31)  39/144 (27)  65/144 (38)  79 (55) |
| **EMPACTA**  **Age – yr - mean**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  No supplemental oxygen  Simple oxygen only  Non-invasive ventilation  **Corticosteroids, n (%)** | **(N=259)**  56,0±14,3  150 (60)  24 (10)  161 (65)  64 (26)  200 (80) | **(N=129)**  55,6±14,9  73 (57)  11 (9)  81 (63)  36 (28)  112 (87) |
| **Salvarini, et al**  **Age – yr - median IQR**  **Male sex – no.(%)**  **Acute respiratory support (%)**  Noninvasive ventilation  **Corticosteroids, n (%)** | **(N = 60)**  61,5 (51,5-73,5)  20 (33)  100  6/60 (10) | **(N = 62)**  60,0 (54,0-69,0)  29 (44)  100  7/62 (11) |
| **Stone, et al**  **Age – yr - median IQR**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  No supplemental oxygen  Simple oxygen only  Noninvasive ventilation  Invasive mechanical ventilation or ECMO  **Corticosteroids, n (%)** | **(N=161)**  61,6 (46,4–69,7)  96(60)  23/161 (14)  133/161 (83)  5/161 (3)  0/161 (0)  18(11) | **(N=82)**  56,5 (44,7–67,8)  45(55)  15/82 (18)  61/82 (74)  5/82 (6)  1/82 (1)  5(6) |
| **TOCIBRAS**  **Age – yr - mean**  **Male sex – no.(%)**  **Acute respiratory support no./total no. (%)**  Supplemental oxygen only  Noninvasive ventilation  Invasive mechanical ventilation or ECMO  **Corticosteroids, n (%)** | **(N=65)**  57,4 (15,7)  44 (68)  39/65 (60)  15/65 (23)  11/65 (17)  45 (69) | **(N=64)**  57,5 (13,5)  44 (69)  28/64 (44)  26/64 (41)  10/64 (16)  47 (73) |

\* We consider high-flow oxygen analagous to noninvasive ventilation. We separated both in this table because that is the way the REMAP-CAP originally reported it.

\*\* These values are derived from Figure 9 in their appendix. Thus, they regard pooled tocilizumab and sarilumab patients.

\*\*\* These values are not 100% reliable. The authors reported diffferent proportions in the manuscript vs. a table in their appendix (eTable 2). The authors of Cochrane’s living review used the manuscript as the reference and so did I.

**Data on respiratory support regard status at randomization.**

**The proportions of patients on corticosteroids regard values after randomization.**